COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis
GMS Infectious Diseases · 28.09.2023 · 11 (Doc03) · Doc03-Doc03
DOI: 10.3205/id000083 ↗Kurz gefasst
Fachartikel in der Zeitschrift GMS Infectious Diseases, erschienen am 28.09.2023. Verfasst von Kathrin Marx und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy, St. Georg Hospital, Leipzig, Germany. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
To ensure the fastest and earliest possible treatment, the German Federal Ministry of Health (BMG) initiated central procurement and nationwide distribution of new drugs against COVID-19. A single centre was used for a retrospective temporal analysis of this procedure.
Methods
A descriptive analysis of hospitalization and treatment of COVID-19 patients with drugs centrally procured by the BMG at St. Georg Hospital, Leipzig, Germany, for the period from 1 March 2020 to 28 February 2023 was employed considering the approval status, evolving guidelines and recommendations of medical societies.
Results
In total, 3,412 patients ≥18 years (54.9% men) with PCR-confirmed SARS-CoV-2 infection were admitted. The mean age was 64 years during the reporting period and 66.1/70.6 years during the first and second COVID-19 waves, respectively. 964 patients (28.2%) received COVID-19 therapy with drugs procured centrally by the BMG. Remdesivir was the most commonly used (63%). SARS-CoV-2 neutralizing monoclonal antibodies represented 23% of the therapies. Peroral antivirals (nirmatrelvir/ritonavir and molnupiravir) were used in 14% of COVID-19 patients, with molnupiravir being insignificant (five prescriptions).
Conclusions
Specific therapeutic approaches were mainly based on antiviral therapy in the early phase of COVID-19 to prevent severe disease progression in vulnerable patient groups. Most drugs had not been approved at the time of central procurement; therefore, prescriptions were given on a case-by-case basis after careful risk–benefit assessments. All available neutralizing monoclonal SARS-CoV-2 antibodies lost efficacy during the pandemic due to different circulating immune escape variants. Remdesivir and nirmatrelvir/ritonavir remained effective therapies in the early phase of COVID-19.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital Pharmacy, St. Georg Hospital, Leipzig, Germany.
- Department of Infectious Diseases and Tropical Medicine, St. Georg Hospital, Leipzig, Germany.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Leipzig University Hospital, Leipzig, Germany.
- Interdisciplinary Center for Infectious Diseases, Leipzig University Hospital, Leipzig, Germany.
Zitieren
APA
Marx, K., Kalbitz, S., Kellner, N., Fedders, M., & Lübbert, C. (2023). COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis. GMS Infectious Diseases, 11(Doc03), Doc03-Doc03. https://doi.org/10.3205/id000083
Vancouver
Marx K, Kalbitz S, Kellner N, Fedders M, Lübbert C. COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis. GMS Infectious Diseases. 2023;11(Doc03):Doc03-Doc03. doi:10.3205/id000083
BibTeX
@article{Marx2023,
author = {Marx, Kathrin and Kalbitz, Sven and Kellner, Nils and Fedders, Maike and Lübbert, Christoph},
title = {COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis},
journal = {GMS Infectious Diseases},
year = {2023},
volume = {11},
number = {Doc03},
pages = {Doc03--Doc03},
doi = {10.3205/id000083}
}
EUVIMED